LAE-005 is under clinical development by Laekna and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase I drugs for Triple-Negative Breast Cancer (TNBC) have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how LAE-005’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
LAE-005 overview
LAE-005 (FAZ-053) is under development for the treatment of advanced solid tumors including chordoma, alveolar soft part sarcoma, triple negative breast cancer. It is administered through intravenous route. The therapeutic candidate is a humanized IgG4 monoclonal antibody which acts by targeting programmed cell death 1 ligand 1 (PD-L1).
It was under development for the treatment of non-small cell lung carcinoma, endometrial cancer and anaplastic thyroid cancer.
Laekna overview
Laekna is a clinical-stage biotechnology company. It develops novel therapies for the treatment of cancer, liver fibrosis, and metabolic diseases. The company is developing its lead product candidate, LAE002 for the treatment of triple-negative breast cancer (TNBC), metastatic castration-resistant prostate cancer (mCRPC), and resistant solid tumors. Its pipeline includes LAE001 to treat metastatic hormone-sensitive prostate cancer (mHSPC); and other drug candidates for cancer treatments. Laekna is also developing a pipeline product range that includes LAE104, LAE105, and LAE106 drug candidates for liver fibrosis treatment. The company was funded by OrbiMed Healthcare Fund, CS Capital, SCGC, GP Healthcare Capital, and Yanchuang Capital. It operates in China, Hong Kong, and the US. Laekna is headquartered in Shanghai, China.
For a complete picture of LAE-005’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
